Cai Dong-Bin

Dr. Cai Dong-Bin


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2019 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
Wei ZhengWei Zheng
Wei Zheng
XZXiao-Min Zhu
Xiao-Min Zhu
QZQing-E Zhang
Qing-E Zhang
GCGen Cheng
Gen Cheng
CDCai Dong-Bin
Cai Dong-Bin
YXYu-Tao Xiang
Yu-Tao Xiang
Objectives: This meta-analysis of randomized controlled trials (RCTs) examined the efficacy and safety of minocycline for three major mental disorders: schizophrenia, bipolar disorder and major depressive disorder (MDD). Methods: A systematic literature search of major electronic databases was conducted. Meta-analysis of clinical efficacy as defined by the respective studies, all-cause discontinuation, adverse drug reactions (ADRs) with standardized mean difference (SMD) and risk ratios (RRs) and their 95% confidence intervals (CI) was conducted using random-effects model. Quality assessment was performed with the Jadad scale and Cochrane risk of bias. Results: Sixteen RCTs ( n=1357) on minocycline (50–300 mg/day) for schizophrenia (13 RCTs, n=1196), bipolar depression (1 RCT, n=49), and MDD (2 RCTs, n=112) were analyzed separately by diagnosis. Twelve RCTs mentioned randomized allocation specifically; the weighted Jadad scores were 4.0. Adjunctive minocycline outperformed placebo in improving total psychopathology [SMD: −0.45 (95%CI: −0.73, −0.16), p=0.002; I2=77%], positive [SMD: −0.15 (95%CI: −0.28, −0.02), p=0.02; I2=0%], negative [SMD: −0.62 (95%CI: −0.95, −0.28), p=0.0003; I2=85%] and general psychopathology scores [SMD: −0.28 (95%CI: −0.53, −0.03), p=0.03; I2=59%] in schizophrenia. Minocycline showed no significant effect on depressive and manic symptoms in both bipolar depression and MDD. Minocycline caused significantly less headache ( p=0.02, number-needed-to-harm=14, 95%CI=5–14) than placebo in schizophrenia. All-cause discontinuation and other ADRs were similar between minocycline and placebo in each diagnostic category. Conclusion: In this meta-analysis, adjunctive minocycline appeared to be efficacious and safe for schizophrenia. However, the efficacy of adjunctive minocycline for bipolar depression or MDD could not be demonstrated. Review registration: PROSPERO: CRD42018102483

28 March 2024 in Asian Journal of Psychiatry
Verified
Journal Article
Closed access
XLXian-Jun Lan
Xian-Jun Lan
XYXin-Hu Yang
Xin-Hu Yang
YMYu Mo
Yu Mo
CDCan-Jin Deng
Can-Jin Deng
XHXing-Bing Huang
Xing-Bing Huang
Wei ZhengWei Zheng
Wei Zheng

21 January 2020 in Psychiatric Quarterly
Verified
Journal Article
Closed access
PDF file
CDCai Dong-Bin
Cai Dong-Bin
Wei ZhengWei Zheng
Wei Zheng
QZQinge Zhang
Qinge Zhang
CNChee H. Ng
Chee H. Ng
GUGabor S. Ungvari
Gabor S. Ungvari
YXYu-Tao Xiang
Yu-Tao Xiang

22 June 2021 in Psychiatric Quarterly
Verified
Journal Article
Closed access
PDF file
CDCai Dong-Bin
Cai Dong-Bin
HZHua-Rong Zhou
Hua-Rong Zhou
WLwannian Liang
wannian Liang
LGLi-Mei Gu
Li-Mei Gu
MHMei He
Mei He
Wei ZhengWei Zheng
Wei Zheng

29 October 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
CHChun Huang
Chun Huang
YFYuan Fang
Yuan Fang
FYFeng Yan
Feng Yan
TWTao Wang
Tao Wang
CDCai Dong-Bin
Cai Dong-Bin
JWJianjun Wang
Jianjun Wang
Introduction Late-life depression (LLD) is a global public health issue, often accompanied by cognitive impairments that can exacerbate the severity of depression and impair social functioning. Despite being a well-established treatment for LLD, the suitability of problem-solving therapy (PST) for individuals with LLD and varying degrees of cognitive impairments warrants further investigation. This paper presents the protocol for a systematic review and meta-analysis of randomised controlled trials (RCTs) aimed at evaluating the effectiveness and acceptability of PST for this specific demographic. Methods/analysis Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we will conduct a systematic review to synthesise existing research on PST for individuals in this demographic. We will comprehensively search multiple databases and sources, including PubMed, EMBASE, the Cochrane Database and APA PsycNET from inception to October 2023, without language, publication year or type restrictions. Relevant studies will be manually screened from the references. Only RCTs involving PST for LLD will be included. The primary efficacy outcome will be the standardised mean difference in total scores on continuous depression severity scales across different comparison arms. Data extraction will be conducted independently by two reviewers (CH and J-JW), and methodological rigour will be assessed using the Cochrane Risk of Bias assessment tool. Subgroup and sensitivity analyses will be performed to investigate the impact of concomitant cognitive impairments and to evaluate the robustness of the findings. Ethics and dissemination The meta-analysis project is expected to be ethically unproblematic and does not require approval from a research ethics committee. The results of this study will be shared through articles in scholarly peer-reviewed journals and presentations in various formats, both print and digital. PROSPERO registration number CRD42023473782